OBJECTIVES: While the best approach to malignant pleural mesothelioma has yet to be demonstrated, surgery remains the mainstay of treatment. We analysed a group of candidates for trimodality treatment, aiming to identify prognostic factors guiding patient selection. Between 2003 and 2015, 83 (31.6%) of the 283 patients with malignant pleural mesothelioma were considered for trimodality treatment to perform induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy. All patients underwent cisplatin-based chemotherapy. Radiotherapy was administered at a mean dose of 50.4 Gy.
INTRODUCTION
Malignant pleural mesothelioma (MPM) remains a major cause of death in patients exposed to asbestos. Even if the standard of care for MPM patients has not yet been established, it is already certain that extrapleural pneumonectomy (EPP) alone is associated with a high rate of treatment failure. However, EPP combined with adjuvant treatments could be considered the only procedure associated with long-term survival for selected patients [1, 2] . One of the latest reviews, conducted by Cao et al. [3] to evaluate survival and perioperative outcome after EPP, suggested that selected patients with MPM may benefit from this type of surgery, but as part of a trimodality treatment (TMT). The median overall survival (OS) for patients undergoing EPP varied from 9.4 to 27.5 months, with 1-, 2-, and 5-year OS rates ranging from 36% to 83%, 5% to 59%, and 0% to 24%, respectively. However, when EPP was part of a TMT, including induction chemotherapy (IC) and postoperative radiotherapy (RT), patients showed a better median OS up to 29.9 months [3] .
Unfortunately, TMT is aggressive and not all patients are able to complete the treatment because of the comorbidities related to surgery and radiotherapy. Thus, patient selection is essential to avoid futile treatment in patients who are unsuitable for TMT.
This study is a retrospective review of our experience of TMT for resectable MPM as a single Italian institution study designed to demonstrate outcome and feasibility and to identify the possible prognostic factors guiding patient selection.
MATERIALS AND METHODS
The Institutional Review Board approved this study, and individual consent was obtained. Prospectively collected data of 283 patients with MPM between 2003 and 2015 were analysed retrospectively. Eighty-three patients (31.6%) were considered for TMT with the intent-to-treat to perform IC, EPP and received RT. Clinical charts were retrospectively reviewed to obtain information that is not routinely entered into the surgical database. Patient follow-up was prospectively updated contacting all those known to be alive at their most recent visit to our Institute. Information of patients lost at follow-up was retrieved through the General Register Office.
Inclusion criteria for TMT were histologically confirmed diagnosis of epithelial or biphasic MPM; clinical Stage T1-3, N0-2 and M0 disease; and no major comorbidity precluding chemotherapy, surgery and radiotherapy. Patients with proven N2 disease were candidates for TMT based on a multidisciplinary decision (single N2 station involved, young age and good response to IC).
Clinical and pathological staging was coded according to the sixth edition of the AJCC Cancer Staging Handbook. In all patients, clinical stage was based on total body computed tomography (CT) scan findings and positron emission tomography with fluorodeoxyglucose. In addition to radiological staging, pulmonary function tests, ventilation perfusions scan and a stress echocardiogram was performed. Mediastinal invasive staging with mediastinoscopy and/or endobronchial ultrasound-transneedle agoaspiration was performed in 9 patients (10.8%) with suspected N2 disease based on CT evidence of enlarged mediastinal nodes (>1.5 cm) and/or pathological positron emission tomography uptake; pathological N2 involvement was confirmed in 6 patients (7.2%).
All patients underwent video-assisted thoracoscopic surgical biopsy, and during thoracoscopic biopsy of the pleura all patients underwent pleurodesis. Pathological staging was based on pathological evaluation of the specimens and on the surgeon's intraoperative findings.
Induction chemotherapy
IC regimens differed over the years, varying with the introduction of new drugs and the development of different institutional treatment guidelines. Most patients were referred to our institute as a tertiary referral centre only at the end of their staging and IC pathways, when decisions and therapeutic plans had already been agreed at the local hospital. All patients underwent cisplatin-based IC and were usually restaged after 3 cycles of IC with total body CT, whereas positron emission tomography with fluorodeoxyglucose was performed in 54 (65%) patients
Extrapleural pneumonectomy
EPP was always performed via double lateral thoracotomy (first thoracothomy through IV-V intercostal space and second thoracotomy through VII-VIII intercostal space) with en bloc excision of the parietal pleura with the entire lung, ipsilateral hemidiaphragm and pericardium. The diaphragm was reconstructed with a synthetic dual mesh (Marlex/Goretex) placed in the anatomic position of the resected diaphragm or with bovine pericardium. The pericardium was reconstructed both on the right and on the left sides to prevent cardiac torsion using synthetic mesh (Vicryl or Gore-Tex) or bovine pericardium. Lymph node dissection was performed in all patients. Surgery was always performed within 4 weeks after the last cycle of IC.
Postoperative complications were classified as minor or major [4, 5] . Postoperative mortality included all deaths within 30 days of EPP or during the same hospital stay. Positive margins were divided into macroscopic (R2, gross disease left in hemithorax at the time of operation) or microscopic (R1, microscopic involvement of inked surgical resection margins). Postoperative bronchopleural fistulas were classified according to the time of onset after the operation: early [1-7 days], intermediate [8-30 days] and late [more than 30 days] [6] . Bronchopleural fistulas occurring more than 90 days from surgery were not considered postoperative complications.
Radiotherapy
RT was given not less than 90 days after surgery and considering the general status of the patient. Three-dimensional conformal RT (3DCRT) or intensity-modulated RT (IMRT), based on different technologies available over the years, was mainly delivered at our Institute (30 of 39 patients; 77%), with a median dose of 50.4 Gy (range 45-54 Gy).
Before 2009, patients were treated with 3DCRT. Planned doses ranged from 45 to 54 Gy with conventional fractionation (1.8 Gy/death); the volume treated was the hemithorax with or without mediastinum. The CTV (the hemithorax) was treated with 2 parallel-opposed fields (antero-posterior and postero-anterior), after CT-based treatment planning. The treatment was performed with 6/18 MV photon beams. The spinal cord was excluded at 40 Gy. Dose volume histograms and electronic portal imaging guaranteed irradiation treatment quality assurance.
After 2009, patients were treated with IMRT: in 10 (25.6%) patients, we utilized the IMRT step and shoot technique with seven 6 MV fixed beams, in 4 patients dynamic IMRT (Rapid Arch) and in 4 (10%) patients tomotherapy. The prescribed dose in this second group was 50 or 50.4 Gy to the planning target volume given with conventional fractionation (1.8-2 Gy/death); the volume treated included the hemithorax involved without the mediastinum. Organs at risk included spinal cord, contralateral lung, heart, oesophagus, liver and both kidneys. Acute toxicity was evaluated using radiation therapy oncology group (RTOG) scale.
Statistical methods
OS was defined from the date of surgery to the date of last contact or death. OS curves were plotted using the Kaplan-Meier method and the log-rank test was used to assess the difference in survival between groups. Univariate and multivariate Cox proportional hazards regression models were used to assess the association between various characteristics, both presurgical (age, sex, smoking status, asbestos exposure, comorbidities, tumour histological subtype and IC) and post-surgical (surgical complications, tumour size, nodal status, presence of metastasis, tumour stage and adjuvant treatment) and OS. Only variables significantly associated with OS at univariate analysis were retained in the multivariate models. A first model was built based solely on presurgical characteristics to identify the prognostic parameters available at the time of surgery. A second multivariate model was built with the addition of postoperative variables. All analyses were performed with SAS software (version 9.2, Cary, NC, USA). All P-values were 2 sided.
RESULTS
We evaluated 83 patients after they had completed IC consisting mainly of a platinum/pemetrexed combination in 73 (88%) patients. Eighty patients had at least 3 cycles of IC, ranging between 3 and 8 cycles. Only 3 patients had 2 cycles of IC due to a heart attack in 1 case and haematological toxicity in 2 cases. Based on the radiological findings, progression to IC was observed in 10.9% (9 of 83) of patients, partial response in 30.1% (25 of 83) and stable disease in 59% (49 of 83).
Of the 83 candidates for EPP, 20 (24.1%) patients were found to be unresectable at the time of thoracotomy. Reasons for explorative thoracotomy were multistation N2-positive nodes in 1 (5%) patient, extensive tumour invasion of great vessels (superior vena cava n = 3, aorta n = 4) in 7 (35%) patients, oesophagus invasion in 1 (5%) and full-thickness chest wall infiltration in 11 (55%) cases. Thus, 63 (75.9%) patients underwent EPP after IC.
Most patients had an epithelial tumour (n = 55; 87.3%). In 3 (4.8%) patients, the diagnosis of sarcomatoid tumour was obtained only after EPP. Forty-two patients (66.7%) had pathological Stage 3 disease, mostly due to lymph node involvement. Eight (12.7%) patients had Stage 4 disease, all with large tumours (pT4) found intraoperatively but none with distant metastasis.
Clinical, surgical and pathological data are reported in Table 1 . Major complications after EPP were observed in 28 (44.4%) patients: 18 (28.5%) underwent rethoracotomy due to haemothorax in 13 (20.6%) patients, gastric herniation in 2 (3.2%), cardiac herniation in 1 (1.6%), empyema in 1 (1.6%) and chylothorax in 1 (1.6%). Postoperative bronchopleural fistula occurred in 6 (9.5%): 4 (6.3%) patients had an early fistula and 2 (3.2%) patients a late fistula. Three (4.8%) patients were treated with thoracostomy, whereas 3 (4.8%) patients had chest tube positioning and antibiotics therapy considering a fistula diameter less than 5 mm.
Three (4.8%) patients had bronchopleural fistula after 90 days: 1 after 8 months, 1 after 14 months and the last one 18 months after surgery; all of them had postoperative RT. Two (3.2%) patients were treated with thoracostomy and 1 (1.6%) with chest tube; these 3 patients died of sepsis.
Minor complications occurred in 45 (71.4%) patients and were the only complications in most cases (n = 32; 50.8%): blood transfusion was the most frequent complication (55.6%), followed by atrial fibrillation (30.2%).
The median intensive care unit stay was 1 day (range 0-21 days) and the median length of total hospital stay was 11 days (range 7-42 days). No intraoperative mortality was observed. Postoperative mortality was 11.1% (7 of 63) due to heart attack in 5 cases and acute respiratory distress syndrome in 2 cases. More details regarding complications and perioperative mortality are reported in Table 2 . Thirty-nine patients (61.9%) underwent adjuvant RT after EPP. Adjuvant RT was not received by 24 (38.1%) patients due to bronchopleural fistula in 5 cases, and poor performance status after surgery in the remaining 19 patients.
Nine patients were treated in other Institutions with only limited details available: they all received 3DCRT with a median dose of 50 Gy (range 45-50.4).
Considering only the 30 patients treated in our Institution, 12 (40.0%) patients were treated with 3DCRT. Acute toxicity was mild (dysphagia G2 in almost all patients and G1 skin erythema), but 2 patients died due to acute respiratory distress syndrome and cardiac arrest immediately after the end of RT. These 2 patients were treated with 54 Gy. In addition, 2 patients did not complete the RT treatment for toxicity (1 for pneumonia and 1 for patient intolerance).
Of the 30 patients, 18 (60.0%) were treated with IMRT. No acute side effect >G2 was recorded. Only 2 of the 3 patients with macroscopically residual disease were treated with RT (1 patient died within 1 month after surgery from cardiac arrest): one was treated with a stereotactic technique (BrainLab VERO System) on the phrenic sinus, the other was treated on the whole hemithorax but was boosted up to 62.5 Gy (2.5 Gy/death) with a simultaneous integrated boost on the thoracoscopic site.
TMT was completed in 37 patients (44.6% of all 83 initial patients). The median treatment time between the beginning of IC and the end of RT was 235 days (range 164-486). Unfortunately, we lacked the date of the diagnosis considering the retrospective nature of the study. Patients were followed for a median duration of 15 months, contributing to 131 personyears of follow-up. Thirty-two patients (rate/month = 2.8%) had recurrence of disease: 19 (rate/month = 1.7%) had local recurrences, 7 (rate/month = 0.6%) distant metastases and 6 (rate/ month = 0.5%) both local and distant. Among the 7 patients with distant metastases, 4 were peritoneal (1 associated with bone metastasis), 2 brain metastasis and 1 liver. For 2 (3.2%) patients with distant metastasis and 1 (1.6%) with local relapse, the date of the event was not available. Postoperative outcomes stratifying by RT administration are reported in Table 3 .
All patients were followed up by chest and abdomen CT scan every 4 months for 2 years, then every 6 months until the fifth year from the end of the TMT; at the end of the 5-year follow-up patients underwent an annual control.
The median OS post TMT was 35.6 months (15.4-42.6), with a 1-, 2-and 3-year OS of 82%, 54% and 48%, respectively. Actuarial survivals according to presurgical and post-surgical characteristics are available in Fig. 1 .
At univariate analysis (Table 4 ; Fig. 1 ) female gender (P = 0.01), epithelial histology (P = 0.02), early stage (Stage 0 and Stage 1; P = 0.04) and TMT (P = 0.0002) were significantly associated with improved survival. Also at multivariable analysis considering presurgical variables, perioperative complications and treatment modalities, and adjusting for age, disease stage and referral centre, female gender, epithelial histology and TMT were significantly associated with survival (Table 4) . 
DISCUSSION
More than 40 years ago, Butchart et al. showed that adjuvant therapy after EPP was essential to achieve an acceptable long-term survival [7] , highlighting the superior outcome in patients treated by a multimodality approach (TMT). Since then, adjuvant chemotherapy and RT have been used in addition to EPP for selected patients with MPM, but the first prospective study assessing the safety and efficacy of a standardized treatment involving IC as part of TMT was only published in 2004 [2] . In that study, Weder et al. stated that IC offered a biological advantage, reflected in a median survival of 23 months compared with a median survival of 10 months during their previous treatment protocol involving EPP followed by adjuvant chemotherapy and RT [2] . More recently, several trials of TMT including IC, surgery and RT for MPM have shown median survivals of 17-24 months [2, [8] [9] [10] [11] . Even in our multicentre study published in 2013, the median OS post-EPP was 18 months, with 1-, 2-and 3-year OS of 65%, 41% and 27%, respectively, but a significant improvement in survival was evident up to 76%, 51% and 37%, respectively, when patients completed the multimodality approach including IC, EPP and RT, showing the importance of TMT [12] .
The present study found a median OS of 15 months, and OS was significantly related to the younger age, female gender, early stage and the administration of RT post-surgery. Our patients who completed the TMT had a median OS up to 35.6 months with 1-, 2-and 3-year OS of 82%, 54% and 48%, respectively, and a lower incidence of local recurrence compared with patients who did not receive RT (1.4% vs 3.0%).
EPP allows higher doses of radiotherapy to the hemithorax by avoiding pulmonary toxicity, with a significant reduction in locoregional relapses [13] . RT treatment has changed over time, and in the last few years, advances in radiation oncology in the form of IMRT have resulted in further improvements in OS and lower toxicity. Tonoli et al. reported a median survival of 46.9 months for patients who underwent IMRT with a median dose of 52 Gy [14] . Gomez (MD Anderson Cancer Center) et al. reviewed 86 patients treated with EPP and postoperative IMRT, reporting 11.3% of G3 or worse pulmonary toxicity [15] . In addition, the European experience (Thieke et al.) of 62 patients treated with TMT showed a good toxicity profile, with just 1 case of symptomatic pneumonitis; patients were treated with both step and shoot static IMRT or tomotherapy, with no differences between the 2 modalities [16] .
In our study, since 2008, all patients underwent IMRT (7 fields static IMRT, Rapid Arch and from 2013 Tomotherapy), with a good tolerability profile, whereas, in the group of patients treated with 3DCRT, 2 patients died soon after the end of therapy for cardiac and pulmonary complications. In fact, dosimetric distribution of IMRT allowed better sparing of heart and contralateral lung, even if the initial experience with this technique showed excessive toxicity [17] . Unfortunately, the aggressiveness of TMT means that only a small percentage of patients are usually able to complete the therapeutic pathway.
Four prospective studies in the literature [18] [19] [20] [21] involved patients treated by TMT, which included IC, EPP and adjuvant RT. These trials showed a perioperative mortality of 0-5%, and a compliance to complete the TMT on an intention-to-treat analysis of 57-71%, with 12-26% of patients failing to proceed to RT after completion of EPP. Perioperative mortality for this challenging surgery may be very high, up to 11% even in experienced hands, with perioperative morbidity rates from 22% to 82% [22] [23] [24] [25] [26] [27] [28] [29] . Even if ours is considered a high volume centre for extended surgery such as EPP (more than 25 EPP in the last 10 years), our perioperative morbidity (considering only major complications) and mortality were 44% and 11%, respectively, leading to a reduction in the number of patients suitable for postoperative RT. Incidence of our postoperative morbidity, in particular haemothorax (20%), was high, probably due to the fact that most of our patients were pT3 for chest wall invasion and required a more challenging surgery to obtain the macroscopical radicality.
Of the 63 patients, 24 (38.1%) did not proceed to RT after EPP, with a significantly lower survival (P = 0.0002) than patients who were able to complete TMT (44.6%).
Considering the high incidence of postoperative morbidity and mortality, and the consequence difficulty to complete the planned TMT treatment, this approach should be reserved exclusively to a very selected group of patients. Female gender, epithelial histology and early stage were significantly associated with a better survival, in particular when the planned TMT treatment was completed, and so they could be considered the best candidate to the TMT approach with a good OS up to 35.6 months. Based on that, exclusion criteria for TMT approach should include older patients, advanced MPM, sarcomatoid tumour and comorbidities, since those patients are likely not able to withstand such an aggressive approach.
Limitations
This study has several limitations. The first is its retrospective nature, which probably limits and influences all of the variables included in the analysis. However, a randomized trial is difficult to conduct considering the rarity and the heterogeneity of this type of tumour, in addition to the long overall treatment time. Only 1 randomized controlled study in the literature (MARS) was designed as a pilot feasibility trial to examine the potential benefits of EPP compared with chemotherapy alone [30] . Unfortunately, it failed to demonstrate either the feasibility of a random allocation of patients (main end-point) or the long-term outcome (tertiary end-point), due to the small number of patients enrolled in the study and their poor compliance with the protocol. Another important bias of our study is the calculation of OS, which started from the day of surgery and not from the day of diagnosis or beginning of IC. Thus, patients who had been diagnosed and received treatments months before EPP will have a median survival longer than that reported in the study. Finally, the heterogeneity of the IC administered to our patients potentially clouds the interpretation of the results.
CONCLUSION
In conclusion, although TMT consisting of IC followed by EPP and postoperative RT seems feasible in selected young female patients with early stage mesothelioma, the long overall treatment time and the strong physical and psychological impact of TMT on the patient made this approach difficult to complete successfully.
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